Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 224

1.

ERCC5 is a novel biomarker of ovarian cancer prognosis.

Walsh CS, Ogawa S, Karahashi H, Scoles DR, Pavelka JC, Tran H, Miller CW, Kawamata N, Ginther C, Dering J, Sanada M, Nannya Y, Slamon DJ, Koeffler HP, Karlan BY.

J Clin Oncol. 2008 Jun 20;26(18):2952-8. doi: 10.1200/JCO.2007.13.5806.

PMID:
18565881
2.

Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.

Fleming ND, Agadjanian H, Nassanian H, Miller CW, Orsulic S, Karlan BY, Walsh CS.

Cancer. 2012 Feb 1;118(3):689-97. doi: 10.1002/cncr.26329. Epub 2011 Jul 12. Erratum in: Cancer. 2012 Nov 1;118(21):5450.

4.

ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer.

Chen J, Xie F, Chen K, Wang D, Jiang H, Li J, Pan F, Chen S, Zhang Y, Ruan Z, Huang H, Zou L, Liang H.

Cancer Biol Ther. 2009 Jul;8(14):1424-30. Epub 2009 Jul 30.

PMID:
19458483
5.

Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-adjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies.

Zamagni C, Wirtz RM, De Iaco P, Rosati M, Veltrup E, Rosati F, Capizzi E, Cacciari N, Alboni C, Bernardi A, Massari F, Quercia S, D'Errico Grigioni A, Dietel M, Sehouli J, Denkert C, Martoni AA.

Endocr Relat Cancer. 2009 Dec;16(4):1241-9. doi: 10.1677/ERC-08-0342. Epub 2009 Sep 11.

6.

Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker.

Yousef GM, Kyriakopoulou LG, Scorilas A, Fracchioli S, Ghiringhello B, Zarghooni M, Chang A, Diamandis M, Giardina G, Hartwick WJ, Richiardi G, Massobrio M, Diamandis EP, Katsaros D.

Cancer Res. 2001 Nov 1;61(21):7811-8.

7.

Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients.

Saldivar JS, Lu KH, Liang D, Gu J, Huang M, Vlastos AT, Follen M, Wu X.

Gynecol Oncol. 2007 Oct;107(1 Suppl 1):S223-9. Epub 2007 Sep 6.

PMID:
17825393
8.

Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.

Eitan R, Kushnir M, Lithwick-Yanai G, David MB, Hoshen M, Glezerman M, Hod M, Sabah G, Rosenwald S, Levavi H.

Gynecol Oncol. 2009 Aug;114(2):253-9. doi: 10.1016/j.ygyno.2009.04.024. Epub 2009 May 14.

PMID:
19446316
9.

Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer.

Steffensen KD, Waldstrøm M, Jeppesen U, Brandslund I, Jakobsen A.

Int J Gynecol Cancer. 2008 Jul-Aug;18(4):702-10. Epub 2007 Oct 24.

PMID:
17961161
10.

ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.

Smith S, Su D, Rigault de la Longrais IA, Schwartz P, Puopolo M, Rutherford TJ, Mor G, Yu H, Katsaros D.

J Clin Oncol. 2007 Nov 20;25(33):5172-9.

PMID:
18024864
11.

Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer.

Cvetkovic D, Pisarcik D, Lee C, Hamilton TC, Abdollahi A.

Gynecol Oncol. 2004 Dec;95(3):449-55.

PMID:
15581945
12.

Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.

Landrum LM, Moore KN, Myers TK, Lanneau GS Jr, McMeekin DS, Walker JL, Gold MA.

Gynecol Oncol. 2009 Feb;112(2):337-41. doi: 10.1016/j.ygyno.2008.10.009. Epub 2008 Nov 28.

PMID:
19041126
13.

Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.

Sun X, Li F, Sun N, Shukui Q, Baoan C, Jifeng F, Lu C, Zuhong L, Hongyan C, YuanDong C, Jiazhong J, Yingfeng Z.

Lung Cancer. 2009 Aug;65(2):230-6. doi: 10.1016/j.lungcan.2008.11.014. Epub 2009 Jan 20.

PMID:
19157633
14.

Unique gene expression profile based on pathologic response in epithelial ovarian cancer.

Spentzos D, Levine DA, Kolia S, Otu H, Boyd J, Libermann TA, Cannistra SA.

J Clin Oncol. 2005 Nov 1;23(31):7911-8. Epub 2005 Oct 3.

PMID:
16204010
15.

Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas.

Têtu B, Popa I, Bairati I, L'Esperance S, Bachvarova M, Plante M, Harel F, Bachvarov D.

Mod Pathol. 2008 Aug;21(8):1002-10. doi: 10.1038/modpathol.2008.80. Epub 2008 May 23.

16.

Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy.

Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Gershenson D, Bast RC, Stec J, Iartchouk N, Smith DI, Ross JS, Hoersch S, Shridhar V, Lillie J, Kaufmann SH, Clark EA, Damokosh AI.

Clin Cancer Res. 2005 Mar 15;11(6):2149-55.

17.

Loss of heterozygosity and lack of mutations of the XPG/ERCC5 DNA repair gene at 13q33 in prostate cancer.

Hyytinen ER, Frierson HF Jr, Sipe TW, Li CL, Degeorges A, Sikes RA, Chung LW, Dong JT.

Prostate. 1999 Nov 1;41(3):190-5.

PMID:
10517877
18.

BTF4/BTNA3.2 and GCS as candidate mRNA prognostic markers in epithelial ovarian cancer.

Le Page C, Ouellet V, Quinn MC, Tonin PN, Provencher DM, Mes-Masson AM.

Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):913-20. doi: 10.1158/1055-9965.EPI-07-0692.

19.

The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer.

Steffensen KD, Waldstrøm M, Jakobsen A.

Int J Gynecol Cancer. 2009 Jul;19(5):820-5. doi: 10.1111/IGC.0b013e3181a12e09.

PMID:
19574766
20.

Klotho expression in epithelial ovarian cancer and its association with insulin-like growth factors and disease progression.

Lu L, Katsaros D, Wiley A, de la Longrais IA, Puopolo M, Yu H.

Cancer Invest. 2008 Mar;26(2):185-92. doi: 10.1080/07357900701638343.

PMID:
18259951

Supplemental Content

Support Center